PT - JOURNAL ARTICLE AU - Bringas Vega, Maria L. AU - Shengnan, Liu AU - Leon, Yanetsy Rodriguez AU - Rodriguez, Ania Mesa AU - Fernandez, Enrique Casabona AU - Llano, Marite Garcia AU - Gonzalez, Daniel Amaro AU - Obaya, Teresita Rodriguez AU - Ruiz, Leslie Perez AU - Teste, Iliana Sosa AU - Razzaq, Fuleah A. AU - Jahanshahi, Marjan AU - Ibañez, Ivonne Pedroso AU - Valdes-Sosa, Pedro TI - NeuroEPO improves cognition in Parkinson’s disease. Preliminary report AID - 10.1101/2022.02.24.22271444 DP - 2022 Jan 01 TA - medRxiv PG - 2022.02.24.22271444 4099 - http://medrxiv.org/content/early/2022/03/28/2022.02.24.22271444.short 4100 - http://medrxiv.org/content/early/2022/03/28/2022.02.24.22271444.full AB - Background Cognitive impairment is a feature of Parkinson’s Disease (PD) from the early stages, but currently, no treatment for cognitive deficits in PD is available. Erythropoietin (EPO) has been studied for its potential neuroprotective properties in neurologic disorders with a beneficial action on cognition.Objective To evaluate if NeuroEPO, a new formulation of EPO with low content of sialic acid, improves the cognitive function in PD patients.Methods A double-blind, randomized, placebo-controlled physician lead trial was conducted. The sample was composed of 26 PD patients (HY stages I-II), where 15 received intranasal NeuroEPO for 5 weeks, and another age and gender-matched 11 patients were randomly assigned to the Placebo. All the samples received 9 months of intensive NeuroEPO treatment during a post-trial. The cognitive functions were assessed using a comprehensive neuropsychological battery before, one week, and 6 months after the first intervention and one week after a 9months post-trial. The effects of NeuroEPO were evaluated using a multivariate linear mixed-effects model using a latent variable for cognition instead of the raw neuropsychological scores.Results A significant and direct effect of the Dose of NeuroEPO (p=0.00003) was found on cognitive performance with a strong positive influence of educational level (p=0.0032) and negative impact of age (p=0.0063).Conclusions These preliminary results showed a positive effect of NeuroEPO on cognition in PD patients with better benefit for younger and higher educated patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04110678Funding StatementThis study was funded by the National Natural Science Foundation of China (NSFC) project 61871105, the CNS Program of UESTC Y0301902610100201, and the Ministry of Public Health and Ministry of Science and Technology of the Republic of CubaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of two institutions: International Center for Neurological Restoration (CIREN) and the Center for Molecular Immunology (CIM), Cuba, following all the guidelines for clinical trials of the Ministry of Public Health of the Republic of Cuba.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://doi.org/10.17605/OSF.IO/M8SJP